[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @PsychedVantage Psychedelic Vantage Psychedelic Vantage posts on X about $cmps, $atai, $mnmd, $cybn the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1461655010958315520/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +219% - X Year XXXXXXX +413% ### Mentions: X [#](/creator/twitter::1461655010958315520/posts_active)  - X Week XX +6.70% - X Month XX -XX% - X Months XXX +216% - X Year XXX +273% ### Followers: XXXXX [#](/creator/twitter::1461655010958315520/followers)  - X Week XXXXX +2% - X Month XXXXX +4.40% - X Months XXXXX +41% - X Year XXXXX +90% ### CreatorRank: undefined [#](/creator/twitter::1461655010958315520/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXXX% **Social topic influence** [$cmps](/topic/$cmps) #4, [$atai](/topic/$atai) #1, [$mnmd](/topic/$mnmd) #2, [$cybn](/topic/$cybn) #1, [$ghrs](/topic/$ghrs) #1, [if you](/topic/if-you) 12.5%, [$abbv](/topic/$abbv) 6.25%, [acquisition](/topic/acquisition) 6.25%, [compound](/topic/compound) 6.25%, [$drug](/topic/$drug) XXXX% **Top accounts mentioned or mentioned by** [@flobrand](/creator/undefined) [@larswilde](/creator/undefined) [@zetaboy69](/creator/undefined) [@thebiotechbear](/creator/undefined) [@culperresearch](/creator/undefined) [@psychedalpha](/creator/undefined) [@0xquasark](/creator/undefined) **Top assets mentioned** [ATAI Life Sciences (ATAI)](/topic/$atai) [AbbVie Inc (ABBV)](/topic/$abbv) ### Top Social Posts Top posts by engagements in the last XX hours "Long post 🚨 $CMPS $MNMD $CYBN $ATAI $GHRS Yes this is a small dataset but we are consistently seeing better outcomes across studies evaluating psychedelics as adjunctive treatments. Whether this reflects a true synergistic effect or simply that patients are in a better psychological or physiological state when they are not required to withdraw from background medications they have been taking for years is not clear yet. It could be both. Janssen originally evaluated Spravato as an adjunctive therapy in patients who were starting a new oral antidepressant. In a monotherapy study they" [X Link](https://x.com/PsychedVantage/status/1997166696142934049) 2025-12-06T04:50Z 1674 followers, 1630 engagements "Am I imagining this or has no one publicly complained about AbbVie acquiring Bretisilocin It feels like this acquisition challenges the whole pharma wants to keep people sick narrative. Curious what others think. $CMPS $MNMD $CYBN $ATAI $GHRS" [X Link](https://x.com/PsychedVantage/status/1989793984185581658) 2025-11-15T20:33Z 1668 followers, 1534 engagements "Had an incredible conversation with @flobrand and @LarsWilde Co-Founders of $ATAI and $CMPS. Full interview in the coming days" [X Link](https://x.com/PsychedVantage/status/1996027999817499132) 2025-12-03T01:25Z 1670 followers, 1902 engagements "Correction and thank you to @Psyched_Alpha for clearing this up as this was not mentioned in the Evercore Healthcare Conference call with $CMPS management. As clarified in PA+ the upcoming COMP005 update will include durability information but not in the form of a MADRS time-course comparison between active and control arms. Instead the readout will look at how different patient-response groups at week X (remitters responders partial responders non-responders) progress through week XX. Since this clarification came from the subscriber-only PA+ analysis Im only sharing the high-level takeaway" [X Link](https://x.com/PsychedVantage/status/1997049774688666074) 2025-12-05T21:05Z 1674 followers, 1735 engagements "2025 has been quite the year for the psychedelic drug development sector: $CMPS $MNMD $CYBN $ATAI $GHRS We have seen positive mid-late stage data coming from multiple companies across a variety of compounds targeting multiple indications. Nearly $XXX million has been raised in follow-on offerings in the past several months and of course big pharma has acquired a compound in the space (and may I add one that doesn't skip the trip) So what do we have to look forward to in 2026 This post will focus on clinical trial readouts: $CMPS to disclose 9-week data (Part A) from COMP006 together with" [X Link](https://x.com/PsychedVantage/status/1997387574600458677) 2025-12-06T19:28Z 1670 followers, 1606 engagements "Big X publicly trade companies are $CMPS $MNMD $CYBN $ATAI and $GHRS. You can make an argument that $DRUG is a psychedelic stock with their earlier stage programs. You also have Solvonis Therapeutics Tryptamine Therapeutics (I think they changed their name again to something else) BetterLife Pharma Clearmind Medicine and Enveric Biosciences. Outside of $CMPS $MNMD $CYBN $ATAI $GHRS and $DRUG the rest are nano caps. I am personally most bullish on $ATAI and $CYBN as I hold shares in both. But if you asked me which companies I am most bullish on in short term medium term and longterm I would" [X Link](https://x.com/PsychedVantage/status/1997467197376004388) 2025-12-07T00:44Z 1669 followers, XXX engagements "Psychedelic Biotech in 2025: What's Next @flobrand and @LarsWilde $ATAI $CMPS $MNMD $CYBN $GHRS" [X Link](https://x.com/PsychedVantage/status/1998437829311877601) 2025-12-09T17:01Z 1673 followers, 6322 engagements "8th Annual Evercore Healthcare Conference in Coral Gables FL $CMPS December X 2025 10:00 AM ET Link:" [X Link](https://x.com/PsychedVantage/status/1995868101930586530) 2025-12-02T14:50Z 1675 followers, 4395 engagements "If you were hoping to analyze durability efficacy data beyond the 6-week endpoint in COMPO05 and COMPO06 its probably time to adjust those expectations. $CMPS Take a listen 👇" [X Link](https://x.com/PsychedVantage/status/1995915292111720572) 2025-12-02T17:57Z 1675 followers, 4298 engagements "$CMPS $MNMD $CYBN" [X Link](https://x.com/PsychedVantage/status/1996077157790183651) 2025-12-03T04:40Z 1675 followers, 1295 engagements "Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January X 2026 10:00am ET $CMPS" [X Link](https://x.com/PsychedVantage/status/1998362612774699270) 2025-12-09T12:02Z 1675 followers, XXX engagements "AtaiBeckley Announces New U.S. Patent Granted for EMP-01 Strengthening Intellectual Property Portfolio $ATAI" [X Link](https://x.com/PsychedVantage/status/1999087484723245310) 2025-12-11T12:02Z 1674 followers, 1204 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@PsychedVantage Psychedelic Vantage
Psychedelic Vantage posts on X about $cmps, $atai, $mnmd, $cybn the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +219%
- X Year XXXXXXX +413%
Mentions: X #
- X Week XX +6.70%
- X Month XX -XX%
- X Months XXX +216%
- X Year XXX +273%
Followers: XXXXX #
- X Week XXXXX +2%
- X Month XXXXX +4.40%
- X Months XXXXX +41%
- X Year XXXXX +90%
CreatorRank: undefined #
Social Influence
Social category influence stocks XXXXX% finance XXXX%
Social topic influence $cmps #4, $atai #1, $mnmd #2, $cybn #1, $ghrs #1, if you 12.5%, $abbv 6.25%, acquisition 6.25%, compound 6.25%, $drug XXXX%
Top accounts mentioned or mentioned by @flobrand @larswilde @zetaboy69 @thebiotechbear @culperresearch @psychedalpha @0xquasark
Top assets mentioned ATAI Life Sciences (ATAI) AbbVie Inc (ABBV)
Top Social Posts
Top posts by engagements in the last XX hours
"Long post 🚨 $CMPS $MNMD $CYBN $ATAI $GHRS Yes this is a small dataset but we are consistently seeing better outcomes across studies evaluating psychedelics as adjunctive treatments. Whether this reflects a true synergistic effect or simply that patients are in a better psychological or physiological state when they are not required to withdraw from background medications they have been taking for years is not clear yet. It could be both. Janssen originally evaluated Spravato as an adjunctive therapy in patients who were starting a new oral antidepressant. In a monotherapy study they"
X Link 2025-12-06T04:50Z 1674 followers, 1630 engagements
"Am I imagining this or has no one publicly complained about AbbVie acquiring Bretisilocin It feels like this acquisition challenges the whole pharma wants to keep people sick narrative. Curious what others think. $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2025-11-15T20:33Z 1668 followers, 1534 engagements
"Had an incredible conversation with @flobrand and @LarsWilde Co-Founders of $ATAI and $CMPS. Full interview in the coming days"
X Link 2025-12-03T01:25Z 1670 followers, 1902 engagements
"Correction and thank you to @Psyched_Alpha for clearing this up as this was not mentioned in the Evercore Healthcare Conference call with $CMPS management. As clarified in PA+ the upcoming COMP005 update will include durability information but not in the form of a MADRS time-course comparison between active and control arms. Instead the readout will look at how different patient-response groups at week X (remitters responders partial responders non-responders) progress through week XX. Since this clarification came from the subscriber-only PA+ analysis Im only sharing the high-level takeaway"
X Link 2025-12-05T21:05Z 1674 followers, 1735 engagements
"2025 has been quite the year for the psychedelic drug development sector: $CMPS $MNMD $CYBN $ATAI $GHRS We have seen positive mid-late stage data coming from multiple companies across a variety of compounds targeting multiple indications. Nearly $XXX million has been raised in follow-on offerings in the past several months and of course big pharma has acquired a compound in the space (and may I add one that doesn't skip the trip) So what do we have to look forward to in 2026 This post will focus on clinical trial readouts: $CMPS to disclose 9-week data (Part A) from COMP006 together with"
X Link 2025-12-06T19:28Z 1670 followers, 1606 engagements
"Big X publicly trade companies are $CMPS $MNMD $CYBN $ATAI and $GHRS. You can make an argument that $DRUG is a psychedelic stock with their earlier stage programs. You also have Solvonis Therapeutics Tryptamine Therapeutics (I think they changed their name again to something else) BetterLife Pharma Clearmind Medicine and Enveric Biosciences. Outside of $CMPS $MNMD $CYBN $ATAI $GHRS and $DRUG the rest are nano caps. I am personally most bullish on $ATAI and $CYBN as I hold shares in both. But if you asked me which companies I am most bullish on in short term medium term and longterm I would"
X Link 2025-12-07T00:44Z 1669 followers, XXX engagements
"Psychedelic Biotech in 2025: What's Next @flobrand and @LarsWilde $ATAI $CMPS $MNMD $CYBN $GHRS"
X Link 2025-12-09T17:01Z 1673 followers, 6322 engagements
"8th Annual Evercore Healthcare Conference in Coral Gables FL $CMPS December X 2025 10:00 AM ET Link:"
X Link 2025-12-02T14:50Z 1675 followers, 4395 engagements
"If you were hoping to analyze durability efficacy data beyond the 6-week endpoint in COMPO05 and COMPO06 its probably time to adjust those expectations. $CMPS Take a listen 👇"
X Link 2025-12-02T17:57Z 1675 followers, 4298 engagements
"$CMPS $MNMD $CYBN"
X Link 2025-12-03T04:40Z 1675 followers, 1295 engagements
"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January X 2026 10:00am ET $CMPS"
X Link 2025-12-09T12:02Z 1675 followers, XXX engagements
"AtaiBeckley Announces New U.S. Patent Granted for EMP-01 Strengthening Intellectual Property Portfolio $ATAI"
X Link 2025-12-11T12:02Z 1674 followers, 1204 engagements